ANIKNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Anika Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$20.22+0.24 (+1.20%)
Close on Oct 19, 2026
- Market cap
- $277.36M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$11.05 (+120.5%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Anika Therapeutics, Inc. grew revenue 5.3% to $120.65M over the twelve months to Jun 30, 2026. Free cash flow was $562.00K.
Revenue
$120.65M
+5.3% vs. a year earlier
Operating income
-$5.12M
TTM Q2 2026
Free cash flow
$562.00K
TTM Q2 2026
EPS, diluted
-$0.27
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $277.36M
- P/E ratio
- –
- Price to sales
- 2.30
- Price to book
- 2.02
- Dividend yield
- –
- Free cash flow yield
- 0.20%
Fundamentals
- Revenue
- $120.65M
- Net income
- -$3.78M
- EPS, diluted
- -$0.27
- Free cash flow
- $562.00K
- Book value per share
- $10.01
- Diluted shares
- 14M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$120.65M+5.3% YoY
Gross profit
$75.00M+14.4% YoY
Operating income
-$5.12M
Net income
-$3.78M
EPS, diluted
-$0.27
Free cash flow
$562.00K
Reported periodTrailing twelve months